Omalizumab and cancer risk: Current evidence in allergic asthma, chronic urticaria, and chronic rhinosinusitis with nasal polyps

[1]  J. Thyssen,et al.  No association between omalizumab use and risk of cancer: a nationwide registry‐based cohort study , 2021, The British journal of dermatology.

[2]  Qingwu Wu,et al.  Efficacy and safety of omalizumab in chronic rhinosinusitis with nasal polyps: a systematic review and meta-analysis of randomised controlled trials , 2021, BMJ Open.

[3]  A. Moreira,et al.  Potential cancer risk with omalizumab? A disproportionality analysis of the WHO's VigiBase pharmacovigilance database , 2021, Allergy.

[4]  D. Dombrowicz,et al.  AllergoOncology: ultra-low IgE, a potential novel biomarker in cancer—a Position Paper of the European Academy of Allergy and Clinical Immunology (EAACI) , 2020, Clinical and Translational Allergy.

[5]  M. Metz,et al.  Omalizumab Updosing in Chronic Spontaneous Urticaria: an Overview of Real-World Evidence , 2020, Clinical Reviews in Allergy & Immunology.

[6]  G. Wells,et al.  Influence of prolonged treatment with omalizumab on the development of solid epithelial cancer in patients with atopic asthma and chronic idiopathic urticaria: A systematic review and meta‐analysis , 2019, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[7]  J. Bernstein,et al.  Effectiveness of omalizumab in adolescent and adult patients with chronic idiopathic/spontaneous urticaria: a systematic review of ‘real-world’ evidence , 2018, Expert opinion on biological therapy.

[8]  L. Macchia,et al.  Long-term "real-life" safety of omalizumab in patients with severe uncontrolled asthma: A nine-year study. , 2017, Respiratory medicine.

[9]  D. De Argila,et al.  Omalizumab in the Treatment of Chronic Inducible Urticaria. , 2017, Actas dermo-sifiliograficas.

[10]  M. Penichet,et al.  AllergoOncology – the impact of allergy in oncology: EAACI position paper , 2017, Allergy.

[11]  K. Rothman,et al.  Incidence of malignancy in patients with moderate-to-severe asthma treated with or without omalizumab. , 2014, The Journal of allergy and clinical immunology.

[12]  J. F. Medina,et al.  Omalizumab Therapy in Severe Asthma: Experience from the Spanish Registry—Some New Approaches , 2012, The Journal of asthma : official journal of the Association for the Care of Asthma.

[13]  W. Busse,et al.  Omalizumab and the risk of malignancy: results from a pooled analysis. , 2012, The Journal of allergy and clinical immunology.